Table 4 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• Detection of BRAF V600E was significantly improved in colorectal cancer patients, enhancing treatment decisions.
• The bridging study subpopulations revealed strong performance metrics for FoundationOne Liquid CDx in identifying BRAF mutations.
• Data showed that using the FoundationOne Liquid CDx improves the identification of key mutations in colorectal cancer.
• The findings indicate that accurate testing for BRAF V600E may lead to more targeted therapies for colorectal cancer patients.